Sumatriptan is Absolutely Contraindicated in NSTEMI
Sumatriptan must never be used in a patient with NSTEMI—it is explicitly contraindicated in patients with ischemic coronary artery disease, including myocardial infarction. 1
Why This is Non-Negotiable
The FDA drug label unequivocally states that sumatriptan is contraindicated in patients with:
- Ischemic coronary artery disease (including history of myocardial infarction)
- Coronary artery vasospasm (including Prinzmetal's angina) 1
Mechanism of Harm
Sumatriptan causes coronary artery vasoconstriction through 5-HT1B receptor activation in coronary vessels 1. In a patient with NSTEMI who already has:
- Acute coronary plaque rupture or erosion
- Compromised myocardial oxygen supply
- Potential for ongoing ischemia
Adding a potent coronary vasoconstrictor would be catastrophic—it could:
- Extend the infarct zone by further reducing coronary blood flow
- Precipitate complete vessel occlusion through vasospasm
- Trigger life-threatening arrhythmias (ventricular tachycardia/fibrillation) 1
- Cause cardiac arrest 2, 3
Real-World Evidence of Harm
Multiple case reports document myocardial infarction, cardiac arrest, and death following sumatriptan use:
- A 30-year-old with minimal cardiovascular risk developed fatal coronary vasospasm with ventricular arrhythmia storm 90 minutes after taking 100mg sumatriptan 3
- A 35-year-old woman experienced cardiac arrest within minutes of first-time subcutaneous sumatriptan use 2
- A 43-year-old healthy man developed transmural MI shortly after oral sumatriptan 4
- A 45-year-old woman with no cardiac risk factors had MI after routine oral sumatriptan 5
These cases occurred in patients without known CAD—the risk in a patient with active NSTEMI is exponentially higher.
Clinical Management Algorithm
If a patient with NSTEMI reports migraine:
Immediately discontinue any triptan medications if already prescribed
Use alternative migraine therapies:
- Simple analgesics (acetaminophen)
- NSAIDs (if not contraindicated by antiplatelet therapy—discuss with cardiology)
- Antiemetics for nausea
- Non-pharmacologic measures (dark room, cold compress)
Document the contraindication prominently in the medical record
Educate the patient that triptans are permanently contraindicated due to their cardiac disease
Coordinate with neurology for long-term migraine prophylaxis once cardiac status stabilizes
Critical Pitfall to Avoid
Do not assume chest pain after sumatriptan is "just migraine-related." The FDA label warns that sensations of chest tightness/pressure are common after sumatriptan but notes: "However, perform a cardiac evaluation if these patients are at high cardiac risk" 1. In NSTEMI, this distinction is irrelevant—the drug should never be given.
Guideline Context
While ACS guidelines 6, 7 focus on anti-ischemic therapies (nitrates, beta-blockers, calcium channel blockers), they do not specifically address sumatriptan because its contraindication in ischemic heart disease is absolute and well-established in the drug's prescribing information. The ESC and AHA/ACC guidelines emphasize avoiding medications that could worsen coronary vasospasm—beta-blockers are contraindicated in vasospastic angina for similar mechanistic reasons 6.
The answer is unequivocal: sumatriptan is contraindicated in NSTEMI, full stop.